EI-1071 tablet, oral

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

HKPDPhase 2$7M

EI-1071 tablet, oral Phase 2 Results Expected

EI-1071 tablet, oral• Mild, Moderate, or Severe Alzheimer's Disease15

Mar 15Estimated

00%

Competitive Landscape

0 competitors in Mild, Moderate, or Severe Alzheimer's Disease

Drug Information

Target Indication

Mild, Moderate, or Severe Alzheimer's Disease

Clinical Trial

Last updated: 2/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

HKPD

Hong Kong Pharma Digital Technology Holdings Ltd

Related Pipeline

Non-segmental Vitiligo

Idiopathic Pulmonary Fibrosis (IPF)